Community Counts: Exploring Transcription Regulation & Immunotherapy for ES-SCLC: Tweetorial #1 Evaluation (ID: i805-4)
*
1.
How many years have you been in practice?
(Required.)
>21
11-20
1-10
<1
*
2.
How many patients with ES-SCLC do you manage per week?
(Required.)
1 to 10
11 to 25
26 to 50
I am not directly involved in patient care
*
3.
Please select the option that best describes your practice setting.
(Required.)
Academic medical center
Community medical center
VA, DOD, or other government
Managed care
Research
Pharmaceutical industry
*
4.
After participating in this activity, how confident are you in the management of patients with ES-SCLC in your practice?
(Required.)
Very confident
Confident
Neutral
Little confidence
No confidence
*
5.
How committed are you to making changes in your practice based on your participation in this activity?
(Required.)
Very committed
Committed
Neutral
Not committed
I do not plan to make changes
If not committed or do not plan to make changes, please indicate reason
*
6.
Which of the following best describes the impact of this activity on your performance?
(Required.)
I gained new strategies/skills/information I can apply to my area of practice
I need more information before I can change my practice
My practice is already consistent with the information presented
This activity will not change my practice
*
7.
Which new strategies/skills/information will you apply to your area of practice? Please select all that apply.
(Required.)
Have a better understanding of patient subsets in which pembrolizumab and nivolumab are most beneficial
Carefully select patients for treatment with pembrolizumab and nivolumab
Consider PD-L1 testing in patients eligible for third-line therapy
Review of trial results prior to treatment selection
Review of guideline recommendation prior to treatment selection
Other (please specify)
*
8.
What barriers do you see to making changes in your practice? Please select all that apply.
(Required.)
Lack of knowledge regarding evidence-based strategies
Lack of convincing evidence to warrant change
Lack of time/resources to consider change
Insurance, reimbursement or legal issues
Conflicting guidelines or evidence
Patient compliance and/or patient resource barriers
Other (please specify)
*
9.
Please rate your level of agreement by checking the appropriate rating.
After participating in today’s activity, I am now better able to:
(Required.)
Strongly agree
Agree
Neutral
Disagree
Strongly disagree
Compare efficacy and safety data for new and emerging treatments for second-line extensive-stage-SCLC (ES-SCLC), as well for immunotherapies approved in subsequent lines
Strongly agree
Agree
Neutral
Disagree
Strongly disagree
Develop a plan of action for selecting appropriate treatment options for ES-SCLC patients who evidence disease progression during or after first-line chemotherapy
Strongly agree
Agree
Neutral
Disagree
Strongly disagree
*
10.
Please rate your level of agreement by checking the appropriate rating.
Narjust Duma, MD, effectively:
(Required.)
Strongly agree
Agree
Neutral
Disagree
Strongly disagree
Presented the Material
Strongly agree
Agree
Neutral
Disagree
Strongly disagree
Avoided Commercial Bias
Strongly agree
Agree
Neutral
Disagree
Strongly disagree
*
11.
Please rate your level of agreement by checking the appropriate rating.
Jacob M. Sands, MD, effectively:
(Required.)
Strongly agree
Agree
Neutral
Disagree
Strongly disagree
Presented the Material
Strongly agree
Agree
Neutral
Disagree
Strongly disagree
Avoided Commercial Bias
Strongly agree
Agree
Neutral
Disagree
Strongly disagree
*
12.
The content presented:
(Required.)
Strongly agree
Agree
Neutral
Disagree
Strongly disagree
Enhanced my current knowledge base
Strongly agree
Agree
Neutral
Disagree
Strongly disagree
Addressed my most pressing questions
Strongly agree
Agree
Neutral
Disagree
Strongly disagree
Promoted improvements or quality in health care
Strongly agree
Agree
Neutral
Disagree
Strongly disagree
Was scientifically rigorous and evidence based
Strongly agree
Agree
Neutral
Disagree
Strongly disagree
Avoided commercial bias or influence
Strongly agree
Agree
Neutral
Disagree
Strongly disagree
13.
As a result of your participation in this activity, what is the one change you are most likely to implement in your practice?
14.
Please list any clinical issues/problems within your scope of practice you would like to see addressed in future educational activities for ES-SCLC:
15.
If you indicated that you perceived commercial bias or influence, please describe: